GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- Charles Rudin named cancer center director at MSK
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure
- Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use
- NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing
